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Abstract Twenty-seven subjectswithmoderate asthma atthe time ofdiagnosis, wellcontrolledunderregular flutica-
sone propionate (FP) (250 mg b.i.d.) for 6 months at least, were randomized to receive in double-blind fashion:FP125 mg
b.i.d. (Group1) or FP 50 mgb.i.d. (Group 2) orplacebo (Group 3) for 3 months or until symptomrecurrence.Daily symp-
tom score and peakexpiratory flow weremonitored. Atthe beginning and atthe end of the study, subjects underwent
methacholine challenge and sputuminduction.Recurrence of symptoms occurred shortly after randomization in all sub-
jects receiving placebo.None from Group1or 2 experienced symptomrecurrence during the study.No significant dif-
ferenceinclinicaland functionaldata, andinsputumeosinophilpercentageswasobservedbetweenthebeginningandthe
end of the study in both Groups 1 and 2. Subjects from Group 3 showed a significant increase of sputum eosinophils
(Po0.05) and a significant decrease in provocative dose of methacholine (Po0.05) when asthma symptoms recurred.
Therefore, very low doses of FP (50 mg b.i.d.) are effective in maintaining for 3 months a good control of the disease in
asthmatics already stable underhigh-dose fluticasone, considering both clinical and functional outcomes andmarkers of
airwayinflammation. r2003 Elsevier Science Ltd.Allrights reserved.
doi:10.1053/rmed.2002.1458, available online athttp://www.sciencedirect.com
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Inhaled corticosteroids are the most e¡ective therapy
in the treatment of chronic asthma (1).Regular use of in-
haled corticosteroids may lead to control of the disease
based on reduction of symptoms, use of rescue therapy
and improvement of lung function (2) as well as to a
signi¢cant improvement of airway in£ammation (3).
The analysis of cells and mediators in induced sputum
is an established and safe method to monitor airway in-
£ammation (4). Several studies reported that eosinophil
percentages in induced sputum increase during exacer-
bations of asthma (5) and after allergen challenge (6),
and decrease after treatment with oral or inhaled corti-
costeroids (5).The analysis of induced sputum is useful in
monitoring the kinetics of airway in£ammation during
progressive reduction of corticosteroid treatment in
asthmatic subjects (7). However, some papers reportedReceived 5 August 2002, accepted in revised form 27 September 2002
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oids on airway in£ammation and their e¡ect on airway
function (8,9).
Clinically, it is very di⁄cult to determine the dose/re-
sponse e¡ect of inhaled corticosteroids and its relation-
ship with airway in£ammation. A dose^response e¡ect
of inhaled corticosteroids has been demonstrated in
asthma control (10) and sputum eosinophilia (11).On the
contrary,Gershman etal. have demonstrated that inmild
asthmatic subjects, similar clinical e¡ect can be obtained
with high (1000 mg/day) or low (100mg/day) doses of £uti-
casone propionate (FP)(12). However, the minimal e¡ec-
tive dose of inhaled corticosteroids in the treatment of
patients with mild or moderate asthma [is not yet de-
¢ned].
The aim of this study was to compare in moderate
asthmatics with no symptoms, low peak expiratory
£ow(PEF) variability, and normal lung function on in-
haled FP(250mg b.i.d), the e¡ect of two di¡erent place-
bo-controlled step-down doses of inhaled FP (125mg
b.i.d. vs. 50mg b.i.d) on clinical ¢ndings, airway respon-
siveness tomethacholine, and airway in£ammation as as-
sessed by induced sputum.
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Subjects
Twenty-seven out of 30 patients (mean age 39717 years,
12 male and 15 female) completed the study (Table 1).
Three subjects failed to complete the study because of
withdrawal of the consent. In all subjects, the diagnosis
of asthma has been performed according to Interna-
tional Guidelines (1) in presence of reversible airway ob-
struction and/or bronchial hyperresponsiveness to
methacholine. Asthma severity was evaluated asmoder-
ate in all subjects, according to one at least of the follow-
ing points: daily symptoms, exacerbations which may
a¡ect activity and sleep, nocturnal symptomsmore than
once aweek, dailyuse of inhaled short-acting b2-agonist,
FEV1 = 60^80% (1). Patients had been regularly treated
with inhaled corticosteroids for at least 6 months (mean
= 8.372.7 months). At the enrolment in the present
study, they had been asymptomatic and stable over the
last 3 months on inhaled corticosteroids only (FP,
250mgb.i.d.) andrescue salbutamol. All patients hadper-
ennial asthma, with no relationshipwith pollen season.
Study protocol
The study had a randomized, double-blind, placebo-con-
trolled design. At the beginning of the study (T1), while
still taking FP 250mg b.i.d., subjects recorded symptom
score and PEF rate twice daily on a diary card over a 2-
week run-in period. After that, on 2 di¡erent days, they
underwent methacholine challenge test and sputum in-
duction.
Inclusion criteria were: diurnal and nocturnal symp-
toms score = 0, low PEF variability [maximal amplitude(-
MA) o10%], and no use of rescue b2-agonists,
throughout all the run-in period. In double blind, rando-
mized order, nine subjects received FP125mg b.i.d, nine
subjects received FP 50mg b.i.d, and nine subjects re-
ceived placebo. All subjects continued to monitor PEF
and symptom score for 3 months or until asthma symp-
toms recurred. At the end of the study (T2), i.e. either
within 5 days from the beginning of asthma symptomsTABLE 1. Characteristics of the examined Subjects
Number 27
Age (years, mean7SD) 39717
Sex (male/female) 12/15
Atopy (Dermatophagoides pteronyssinus/) yes/no 18/9
Smoke (no/ex) 21/6
Duration of asthma (years, mean7SD) 974
FEV1 (l, mean7SD) 3.2370.91
FEV1 (% of predictedvalue, median [range]) 96[76-122]
Baseline PD20FEV1methacholine (mg,GM) 0.220or 3 months after randomization, all subjects repeated
methacholine challenge and sputum induction.
Methacholine challenge test
Methacholine (Sigma, St. Louis, MO, U.S.A.) was deliv-
eredby a Devilbiss 646 jet nebulizer using the procedure
described elsewhere (13). PD20 (the cumulative dose pro-
ducing 20% fall in FEV1) was computed.
Symptomscore and PEFFlowmonitoring
Subjects monitored PEF mini-Wright Peak Flow Meter
(PFM) 2 times daily for14 consecutive days at the begin-
ning of the study (run-in period). They recorded daily
asthma symptoms (cough, wheeze and/or dyspnoea) on
a diary card (from 0 to 9). PEF variability was assessed as
daily MA ((highest-lowest value) /mean daily value x100).
Sputum induction and sputumprocessing
Sputum was induced and processed according to the
method previously described (14). In our laboratory, the
reproducibility of di¡erential cell percentages has been
evaluated (15).
Statistical analysis
FEV1, PEF and indices of PEF variability are expressed as
mean (standard deviation, SD). PD20 methacholine is ex-
pressed as geometric mean and was log transformed
for statistical analysis. Sputum eosinophil percentages
are expressed asmedian [range].
Analysis of variance (ANOVA) was used to compare
observations for normally distributed data (FEV1, FEV1%
predicted, logPD20 methacholine and mean PEF), and
Kruskal^Wallis or Wilcoxon tests were used for non-
normally distributeddata (symptom score,PEF,MA, spu-
tum eosinophil percentages).
RESULTS
At thebeginningof the study (T1), the functional and clin-
ical ¢ndings were not signi¢cantly di¡erent among the
groups considered (Table 2). At T1, nine out of 27 (33%)
subjects showed sputum eosinophil percentages42%.
Recurrence of symptoms occurred shortly after ran-
domization (median [range]: 7 [3^8] weeks) in all sub-
jects receiving placebo (Group 3). None from Group 1
(FP125mg b.i.d.) or fromGroup 2 (FP 50mg b.i.d.) experi-
enced recurrence of asthma symptoms.
At T2, subjects of Group 3 showed an increase in asth-
ma symptoms and PEF variability, and a decrease inmean
PEF and PD20 methacholine in comparison with baseline
evaluation (T1).On the other hand, no changes between
TABLE 2. Characteristics ofthe examined subjects atthe beginning (T1) and atthe end ofthe study (T2)
Group1 Group 2 Group 3
T1 T2 T1 T2 T1 T2
Number 9 9 9
Age (years, mean7SD) 35715 40717 41720
Sex (male/female) 5/4 3/6 7/2
Smoke (no/ex) 6/3 7/2 8/1
Duration of asthma (years, mean7SD) 873 7.872 1276
Atopy (yes/no) 6/3 6/3 6/3
FEV1 (l, mean7SD) 3.3870.92 3.3971.0 3.6370.96 3.6171.0 3.0271.02 2.870.98
FEV1, % Predictedmedian (range) 100[77^118] 100[76^117] 104[85^114] 95[86^115] 100[79^118] 91[72^115]
PD20FEV1methacholine (mg,GM) 0.720 0.800 0.420 0.460 0.340 0.110*,**
Sputumeosinophils(%), median (range) 1.9 [0^4.7] 1.6 [0^8.9] 3.3 [0.4^16.6] 1.3 [0^9.9] 0.8 [0^2.7] 13.1 [0.6^44.9]*,**
Maximal amplitude(%), median (range) 4[2^9] 6[3^17] 3[1^8] 5[2^7] 4[2^9] 10[5^28]*,**
Mean PEF (l/min), mean7SD 4837144 4817146 4947140 5047140 3817125 3297112*,**
Symptom score 0 0.270.4 0 0.170.3 0 6.871.9*,**
Rescue salbutamol (numberof pu¡s) 0 0.170.4 0 0 0 6.771.0*,**
SD: standard deviation.
*Po0.05 by Kruskal^Wallis between Group 3 and other groups atthe end ofthe study
**Po0.05 byWilcoxontest between Group 3 at T1and Group 3 at T2.
The three studygroupswere separatelyconsidered.Group1= subjects treatedwith £uticasone propionate125 mgb.i.d.Group
2= subjects treatedwith FP 50 mgb.i.d.Group 3= subjects treatedwith placebo.
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subjects of Groups1and 2. At the end of the study (T2),
subjects of Groups 1 and 2 were signi¢cantly di¡erent
from subjects of Group 3 as regards all clinical and func-
tional data.
In subjects from Group 3, sputum eosinophils percen-
tages were signi¢cantly higher inT2 than inT1, and inT2
themedianvalue of sputumeosinophils was considerably
higher than in other groups (Fig.1).On the contrary, per-
centages of sputumeosinophilswas low inGroup1and in
Group 2, both at T1 and T2 [Group 1: 1.9% (0^4.7) and
1.6% (0.8^8.9); Group 2: 3.3% (0^16.6) and1.3% (0^9.9)].
At T1and T2 no signi¢cant correlation was observed be-
tween PD20 methacholine and eosinophil percentages in
induced sputum in all subjects (T1: r=0.09, P=0.60; T2:
r=0.3, P=0.12)
DISCUSSION
This study demonstrates that in the management of
chronic asthma, very low doses of FP (like 50mg b.i.d.)
are e¡ective in controlling symptoms, pulmonary func-
tion, airway responsiveness tomethacholine, and airway
in£ammation in patients already stable with FP 250mg
b.i.d.The deterioration in asthma control in the placebo
group within 3 months actually con¢rms the signi¢cant
e⁄cacy of low doses of FP in controlling asthma and in
preventing the recurrence of asthma symptoms. These
¢ndings are consistent with previous observations on
the e⁄cacyof lowdoses of inhaledcorticosteroids, oftenin single administration daily, in patients already stable
after long-term treatment with higher doses of inhaled
corticosteroids (16,17).
The clinical implications of these ¢ndings could be im-
portant.Firstly, the e⁄cacy of very low doses of inhaled
corticosteroids, not yet fully established as e¡ective in
adult asthmatics, may indicate that a large part of asth-
matic subjects are probably over-treated, with risk of
side e¡ects from long-term treatment with inhaled cor-
ticosteroids. Secondly, there should be no objective rea-
son in mild-to-moderate asthma for starting with high
doses of inhaled corticosteroids and successively redu-
cingdoses until theminimal e¡ective dose of inhaled cor-
ticosteroids (step-down treatment). This method could
leave patients on high dose of inhaled corticosteroids
for a long timewithoutprovenbene¢t in asthma control.
In e¡ect, some studieshave shown that startingwith low
or high doses of inhaled budesonide or £uticasone in-
duces similar bene¢cial e¡ects in corticosteroid-naive
patients (12,18).
Current guidelines of asthma treatment recommend,
as ¢rst step in adult asthmatic subjects requiring regular
treatment, low doses of inhaled corticosteroids. These
low doses are reported as equal or lower than 400^
500mg daily (1), but there is no indication onwhich could
be the lowest e¡ective dose of inhaled corticosteroids in
adults.Our study shows that, in asthmatic subjects pre-
viously treated with FP 250mg b.i.d., FP 50mg b.i.d. was
e¡ective inmaintaining a good control of symptoms, air-
way hyperresponsiveness and sputum eosinophilia. This
observation is in agreement with other studies which
FIG. 1. Sputum eosinophil percentages at the beginning of the study on (FP) 250 mg b.i.d. (T1) and at the end of the study (T2) on FP
125 mgb.i.d. for Group1, on FP 50 mgb.i.d. for Group 2, andonplacebo for Group 3.The endofthe studywas either atthe time ofthe
recurrence of symptoms (Group 3=nine subjects) or after 3-month follow-up (Group1=nine subjects;Group 2=nine subjects). Hor-
izontal bars representmedianvalues.
466 RESPIRATORYMEDICINEsuggest to reconsider the e¡ectiveness of very lowdoses
of inhaled corticosteroids in the treatment of asthma,
particularly in subjects already stable after long-term
treatment with high dose inhaled corticosteroids
(9,12,18).
We cannot assess for the comparison between two
di¡erent doses of FP (125 vs. 50mg b.i.d.) because of the
low number of examined subjects. An equivalence study
should have required a considerable higher number of
subjects, and possibly a longer period of examination.
We can only state that two doses of FP were e¡ective
in preventing the recurrence of asthma symptoms in a
period of 3 months, but we cannot evaluate whether FP
50mg b.i.d. was really as e¡ective as FP125mg b.i.d.
Another important implication of our results is about
airway in£ammation.The analysis of induced sputum can
noweasily detect the e¡ect of therapy on airway in£am-
mation. In our study, asthmatic subjects on FP 250mg
b.i.d. with no symptoms, low PEF variability, no use of
rescue therapy, showed a low median value of sputum
eosinophil percentages.However, about 30%of our asth-
matic patients showed sputum eosinophilia (=2%) (19)
despite optimal clinical control. These ¢ndings suggest
that airway in£ammation may not be optimally con-
trolled despite a good control of symptoms and lung
function in chronic asthmatics. At the present time, it is
not knownwhether a treatmentdirected on the controlof airway in£ammation rather than on the control of
symptoms and functional abnormalities could be more
e¡ective in the long-term follow-up of asthmatic sub-
jects. Some studies suggested that a treatment aimed
to improve bronchial hyperresponsiveness could be
more e¡ective than the standard therapy based on
symptoms and pulmonary function (20); this is not
knownyet as regards sputum eosinophils (21).
In conclusion, it was found that very low doses of in-
haled FP are e¡ective in controlling asthmatic subjects
already stable after long-term treatment with higher
doses of FP. These e¡ects are similar both considering
clinical and functional outcomes of asthma and consider-
ing markers of airway in£ammation. These ¢ndings
highlight the frequent Lover-treatmentL of asthmatics
and the potential of reducing the dose of inhaled
corticosteroids in stable asthmatics.Therefore, the clin-
ical implication of our study is to maintain as low as pos-
sible the dose of inhaled corticosteroids in asthmatic
subjects.
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